Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study

Table 3 Univariate analysis of factors associated with overall survival

Factor	Comparison	Hazard Ratio	Lower 95%CL	Upper 95%CL	P-value
Gender	F vs. M	1.02	0.77	1.36	0.8857
Pathologic Stage	IIA vs. I	1.08	0.51	2.32	0.8368
	IIB vs. I	1.77	0.93	3.37	0.0805
Chemotherapy for rPDAC	Yes vs. No	0.31	0.23	0.43	<.0001
Margin Negative	Yes vs. No	0.75	0.54	1.04	0.0860
Lymphovascular Invasion	Yes vs. No	1.53	1.11	2.10	0.0089
Perineural Invasion	Yes vs. No	0.97	0.64	1.46	0.8731
Co-morbid Conditions	Yes vs. No	1.11	0.83	1.50	0.4805
Diabetes Mellitus	Yes vs. No	0.90	0.67	1.22	0.5040
Radiotherapy for rPDAC	Yes vs. No	0.57	0.35	0.92	0.0207
Recurrence site	Distant vs. Local	1.15	0.83	1.59	0.3979
^aPerioperative therapy	Yes vs. No	0.80	0.56	1.14	0.2220
rPDAC chemotherapy group	Non-Standard Combination vs. Single Agent	0.82	0.47	1.43	0.4764
rPDAC chemotherapy group	Standard Combination vs. Single Agent	0.54	0.31	0.92	0.0246
Ca19–9 at recurrence	<1000 U/ml vs >1000 U/ml	1.007	0.999	1.016	0.0914
CA19–9 at diagnosis	<1000 U/ml vs >1000 U/ml	1.073	1.038	1.108	<.0001

rPDAC recurrent pancreatic ductal adenocarcinoma
^aPerioperative therapy: combination of patients who received neoadjuvant or adjuvant therapy

ISSN: 1471-2407